19th Clinical Trials on Alzheimer’s Disease (CTAD)
The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda.
Plan to attend our expert-led poster sessions during the conference and learn how we can provide the expertise and tools needed to achieve your clinical research goals efficiently and effectively.
Poster Session 1
Dates and time: November 16, 2026, 2:00 pm ET – November 17, 2026, 5:30 pm ET
P077 (Imaging MRI & PET)
Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies
Authors: Christopher C. Rowe, Austin Health / University of Melbourne; David Scott, Clario, Philadelphia, United States Serge Gauthier, McGill University; Kenji Ishii, Tokyo Metropolitan Institute for Geriatrics and Gerontology; Keith Johnson, Harvard Medical School; Sterling C. Johnson, University of Wisconsin-Madison; Susan Landau, University of California Berkeley; Eric Reiman, Banner Alzheimer’s Institute; Koen Van Laere, University Hospitals Leuven; Luca Passamonti, Lantheus; Alison Long, Enigma Biomedical Group; Sulantha S. Mathotaarachchi, Enigma Biomedical Group; Hartmuth C. Kolb, Enigma Biomedical Group; Antoine Leuzy, Enigma Biomedical Group; Samantha Budd-Haeberlein, Enigma Biomedical Group
P109 (Imaging MRI & PET)
Comparison of test-retest variability and longitudinal stability of total intracranial volume measurement between atlas-based and segmentation-based MRI methods
Authors: Thomas Cajgfinger, Clario; Alessandro Delmonte, Clario; Madhura Ingalhalikar, Clario; Chris Conklin, Clario; Joel Schaerer, Clario; Meredith Burke, Clario; David Scott, Clario; Luc Bracoud, Clario
P110 (Imaging MRI & PET)
Longitudinal evolution of enlarged perivascular spaces across the AD continuum
Authors: Luc Bracoud, Clario; Alessandro Delmonte, Clario; Thomas Cajgfinger, Clario; Madhura Ingalhalikar, Clario; Chris Conklin, Clario; Joel Schaerer, Clario; Meredith Burke, Clario; David Scott, Clario
P131 (Clinical Assessment / Digital Endpoints)
Machine Learning Improves Error Detection for the CDR through Precision Endpoint Protection
Authors: Selam Negash, Clario; Matt Welch, Clario; Danielle Di Gregorio, Clario; Dorothee Schoemaker, Clario; Shelly Steele, Clario, Clario; Briana Webber-Lind, Clario; Barbara Echevarria, Clario; David Ju, Clario; Chris Randolph, Clario
Poster Session 3
Date: November 19, 2026
Time: 7:15 am – 5:00 pm ET
P425 (Cognitive & Functional Outcomes)
Experience, Not Education, Drives Rater Performance on the Clinical Dementia Rating Scale
Authors: Dorothee Schoemaker, Clario; Danielle DiGregorio, Clario; Selam Negash, Clario;Cong Liu, Clario; Chris Randolph, Clario
P431 (Cognitive & Functional Outcomes)
ADAS-Cog 11 vs 13 in early Alzheimer’s disease: sensitivity to longitudinal change
Authors: Catarina Cunha, Clario; Matt Welch, Clario; Daema Pina Delgado, Clario; Zsolt Ternei, Clario; Selam Negash, Clario; Chris Randolph, Clario; Danielle DiGregorio, Clario
Additional posters that feature Clario authors (not presented by Clario):
Poster Session 1
Dates: November 16 – November 17, 2026
Time: 2:00 pm – 5:30 pm ET
P074 (Imaging MRI & PET)
Laromestrocel preserves brain volume and cognitive function in Alzheimer’s disease by inhibiting neuroinflammation
Authors: BRIAN Rash. Longeveron Inc.; Sofya Levitina, Longeveron Inc.; Jeffrey Botbyl, Provonix Inc.; Chris Conklin, Clario; Madhura Ingalhalikar, Clario; Joshua Hare, Longeveron Inc.
P012 (Clinical Trials – Phase IIb & III)
The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial
Authors: S. Abushakra, Alzheon, Inc.; E. Liang, Alzheon, Inc.; M. Sabbagh, Barrow Neurological Institute; S. Cohen, Toronto Memory Clinic; D. Watson, Alzheimer’s Research and Treatment Center; E. Macsweeney, Re:Cognition Health; J. Sampalis, McGill University and Université de Montréal; J. Barakos, Clario & Pacific Medical Center; J. Kesslak, Alzheon, Inc.; J. Hey, Alzheon, Inc.; S. Flint, Alzheon, Inc.; R. McLaine, Alzheon, Inc.; A. Albayrak, Alzheon, Inc.; A. Power, Alzheon, Inc.;, M. Tolar, Alzheon, Inc.